Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials: A Meta-analysis

Overview of attention for article published in JAMA Oncology, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

So far, Altmetric has seen 4 public wall posts from 1 users.

This analysis of data submitted to the US FDA indicates that landmark endpoints such as overall survival at one year can serve…

This meta-analysis explores milestone rate, a proposed intermediate end point for immunotherapy trials among patients with non–sm…

Landmark endpts like 1 yr OS may serve as early surrogate for broad activity of NCSLC treatment, especially with immunotherapy.

This analysis of data submitted to the US FDA indicates that landmark endpoints such as overall survival at one year can serve…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity.